Ipsen Reports Strong First Quarter 2017 Sales Growth Of 19,1%

PARIS--(BUSINESS WIRE)--Regulatory News:

“After the successful closing of the Onivyde® transaction, our largest acquisition to date, we are focused on the successful execution of the Onivyde® and Cabometyx® launches. These two important products strengthen our presence in Oncology and will contribute meaningfully to our top-line growth and profitability in the coming years.”

Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical group, today announced sales for the first quarter of 2017.

First quarter 2017 unaudited IFRS consolidated sales

(in million euros) Q1 2017 Q1 2016

% Change at
constant
currency

Specialty Care 366.5 288.1 25.4%
Consumer Healthcare 71.6 73.9 -5.3%
Group Sales 438.0 362.0 19.1%
MORE ON THIS TOPIC